Interleukin-6 controls recycling and degradation, but not internalization of its receptors.


Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
Historique:
received: 10 12 2020
revised: 10 02 2021
accepted: 16 02 2021
pubmed: 22 2 2021
medline: 31 8 2021
entrez: 21 2 2021
Statut: ppublish

Résumé

Interleukin-6 (IL-6) is a cytokine implicated in proinflammatory as well as regenerative processes and acts via receptor complexes consisting of the ubiquitously expressed, signal-transducing receptor gp130 and the IL-6 receptor (IL-6R). The IL-6R is expressed only on hepatocytes and subsets of leukocytes, where it mediates specificity of the receptor complex to IL-6 as the subunit gp130 is shared with all other members of the IL-6 cytokine family such as IL-11 or IL-27. The amount of IL-6R at the cell surface thus determines the responsiveness of the cell to the cytokine and might therefore be decisive in the development of inflammatory disorders. However, how the expression levels of IL-6R and gp130 at the cell surface are controlled is largely unknown. Here, we show that IL-6R and gp130 are constitutively internalized independent of IL-6. This process depends on dynamin and clathrin and is temporally controlled by motifs within the intracellular region of gp130 and IL-6R. IL-6 binding and internalization of the receptors is a prerequisite for activation of the Jak/STAT signaling cascade. Targeting of gp130, but not of the IL-6R, to the lysosome for degradation depends on stimulation with IL-6. Furthermore, we show that after internalization and activation of signaling, both the IL-6R and gp130 are recycled back to the cell surface, a process that is enhanced by IL-6. These data reveal an important function of IL-6 beyond the pure activation of signaling.

Identifiants

pubmed: 33610555
pii: S0021-9258(21)00207-6
doi: 10.1016/j.jbc.2021.100434
pmc: PMC8010714
pii:
doi:

Substances chimiques

Cytokines 0
IL6R protein, human 0
Interleukin-6 0
Receptors, Interleukin 0
Receptors, Interleukin-6 0
Cytokine Receptor gp130 133483-10-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100434

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.

Références

J Immunol. 2018 May 15;200(10):3547-3555
pubmed: 29626088
Eur J Immunol. 1993 Feb;23(2):473-80
pubmed: 8436181
Mol Biol Cell. 2010 Aug 1;21(15):2797-807
pubmed: 20554759
FEBS Lett. 2000 Mar 17;470(1):15-9
pubmed: 10722837
J Biol Chem. 1994 Jul 22;269(29):19014-20
pubmed: 8034658
J Cell Sci. 2014 Jan 15;127(Pt 2):341-53
pubmed: 24213527
Cytokine Growth Factor Rev. 2016 Dec;32:63-73
pubmed: 27461871
J Cell Sci. 2001 Jan;114(Pt 2):353-65
pubmed: 11148137
Traffic. 2012 Nov;13(11):1532-46
pubmed: 22882974
Mol Pharmacol. 2015 Oct;88(4):660-75
pubmed: 26180046
FEBS Lett. 1992 Jul 20;306(2-3):219-22
pubmed: 1321736
J Biol Chem. 2015 Oct 23;290(43):26059-71
pubmed: 26359498
Nature. 2015 Jan 22;517(7535):493-6
pubmed: 25517096
Nature. 2015 Jan 22;517(7535):460-5
pubmed: 25517094
J Clin Invest. 2011 Sep;121(9):3375-83
pubmed: 21881215
Cell Rep. 2016 Jul 26;16(4):1067-1081
pubmed: 27425614
Ann N Y Acad Sci. 1995 Jul 21;762:410-2
pubmed: 7668544
J Biol Chem. 2011 Apr 29;286(17):14804-11
pubmed: 21454673
Cytokine. 2014 Nov;70(1):11-20
pubmed: 24986424
Nat Rev Drug Discov. 2018 Jun;17(6):395-412
pubmed: 29725131
Biol Chem. 2016 Aug 1;397(8):695-708
pubmed: 27071147
J Biol Chem. 2016 Aug 5;291(32):16892-903
pubmed: 27298320
J Biol Chem. 2003 Oct 3;278(40):38829-39
pubmed: 12832423
Cell Signal. 2006 Aug;18(8):1140-6
pubmed: 16274960
Eur J Biochem. 1994 Jul 1;223(1):265-74
pubmed: 8033901
J Biol Chem. 2011 Dec 16;286(50):42959-70
pubmed: 21990364
Science. 1994 Jan 7;263(5143):92-5
pubmed: 8272873
Sci Rep. 2016 May 06;6:25550
pubmed: 27151651
Nature. 2009 Jan 8;457(7226):200-4
pubmed: 19020503
PLoS Biol. 2017 Jan 6;15(1):e2000080
pubmed: 28060820
J Biol Chem. 2012 Apr 20;287(17):13743-51
pubmed: 22523320
Nat Immunol. 2015 May;16(5):448-57
pubmed: 25898198
Nat Rev Mol Cell Biol. 2005 Feb;6(2):112-26
pubmed: 15687999
Gene Ther. 2002 Apr;9(8):477-87
pubmed: 11948372
J Cell Biol. 1996 Nov;135(4):913-24
pubmed: 8922376
Eur J Cell Biol. 2011 Jun-Jul;90(6-7):484-94
pubmed: 21145125
Annu Rev Pharmacol Toxicol. 2012;52:199-219
pubmed: 21910626
FEBS Lett. 1998 Dec 18;441(2):231-4
pubmed: 9883890
Science. 1994 Jan 7;263(5143):89-92
pubmed: 8272872
J Biol Chem. 1996 Mar 8;271(10):5487-94
pubmed: 8621406
J Cell Sci. 2000 Oct;113 ( Pt 20):3593-602
pubmed: 11017875
Cell Commun Signal. 2014 Mar 10;12:14
pubmed: 24612692

Auteurs

Charlotte M Flynn (CM)

Institute of Biochemistry, Kiel University, Kiel, Germany.

Birte Kespohl (B)

Department of Pathology, Otto-von-Guericke-University Magdeburg, Medical Faculty, Magdeburg, Germany.

Tina Daunke (T)

Institute of Biochemistry, Kiel University, Kiel, Germany.

Yvonne Garbers (Y)

Institute of Psychology, Kiel University, Kiel, Germany.

Stefan Düsterhöft (S)

Institute of Pharmacology and Toxicology, RWTH Aachen University, Aachen, Germany.

Stefan Rose-John (S)

Institute of Biochemistry, Kiel University, Kiel, Germany.

Johannes Haybaeck (J)

Department of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria; Diagnostic & Research Center for Molecular Biomedicine, Institute of Pathology, Medical University of Graz, Graz, Austria.

Juliane Lokau (J)

Department of Pathology, Otto-von-Guericke-University Magdeburg, Medical Faculty, Magdeburg, Germany.

Samadhi Aparicio-Siegmund (S)

Institute of Biochemistry, Kiel University, Kiel, Germany.

Christoph Garbers (C)

Department of Pathology, Otto-von-Guericke-University Magdeburg, Medical Faculty, Magdeburg, Germany. Electronic address: christoph.garbers@med.ovgu.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH